Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs 10X Genomics Inc (TXG) Price & Performance

iShares iBoxx $ High Yield Corporate Bond ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

iShares iBoxx $ High Yield Corporate Bond ETF vs 10X Genomics Inc — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.63, while 10X Genomics Inc trades at $57.79 (market cap $7.61B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.

HYGTXG
Sector
Fixed IncomeHealth
52-Week High
$81.32$58.57
52-Week Low
$78.72$11.34
Market Cap
$7.61B
Enterprise Value
$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares iBoxx $ High Yield Corporate Bond ETF

HYG, the iShares iBoxx $ High Yield Corporate Bond ETF, trades at $79.615, up 0.17% on the day. Technical indicators show a bearish trend with key support at $79 and resistance at $80. Recent news highlights bond market volatility amid inflation concerns and rising oil prices, while the ETF faces criticism for underperformance versus peers.

The outlook for HYG is cautious due to bearish technicals and macroeconomic headwinds like potential Fed rate hikes. Risks include high-yield credit exposure and inflation sensitivity, but the ETF's 6.5% dividend yield may attract income-focused investors amid broader bond market inflows.

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Returns comparison

Trailing returns across standard periods

About iShares iBoxx $ High Yield Corporate Bond ETF

HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.

Read more on HYG

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG